|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
Part 6: Inactivation Methods Grouped by Virus
by Gail Sofer, BioReliance, Dorothy C. Lister, and Jeri Ann Boose
Advertisement
Articles in this issue
over 22 years ago
Part 1: Skin, Bone, and Cellsover 22 years ago
BioPharm International's Virus Inactivation Series: A Prefaceover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Inactivation of Viruses: An Introduction to the Seriesover 22 years ago
Part 5: Disinfectionover 22 years ago
Part 2: Red Blood Cells and PlateletsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
3
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
4
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
5
